The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats

Journal of Neural Transmission

Volumn 107, Issue 4, 2000, Pages 409-417

  Prat, G ^a,b,c   Perez V ^b   Rubio, A ^a,b   Casas, M ^a,b   Unzeta, M ^b  

^a Inst Recerca l'Hosp S Creu I S   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Hospital de la Sta Creu i St Pau   (Spain)

Author keywords

L DOPA; MAO B inhibitors; Parkinson's disease; Turning behavior

Indexed keywords

CLORGYLINE; DOPAMINE UPTAKE INHIBITOR; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; OXIDOPAMINE; PF 9601N; SELEGILINE; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0034070031     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020070083     Document Type: Article

References (21)

1. Anderson PH (1989) The dopamine uptake inhibitor GBR12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166: 493-504
2. Cruces MA, Elorriaga C, Fernández-Alvarez E (1991) Acetylenic and allenic derivatives of 2-(5-metoxyindolyl) and 2-(5-hidroxyindolyl)methylamines: synthesis and in vitro evaluation as monoamine oxidase inhibitors. Eur J Med Chem 26: 33-41
3. Finberg JPM, Wang J, Goldstein DS, Kopin IJ, Bankiewicz KS (1995) Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J Neurochem 65: 1213-1220
4. Fozard JR, Palfreyman MG, Robin M, Zreika M (1986) Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-DOPA without modifying its cardiovascular effects. Br J Pharmacol 87: 257-264
5. Galler RM, Hallas BH, Fazzini E (1996) Current trends in the pharmacologie and surgical treatment of Parkinson's disease. J Am Osteopath Assoc 96: 228-232
6. Heeringa MJ, d'Agostini F, DeBoer P, DaPrada M, Damsma G (1997) Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior. J Neural Transm 104: 593-603
7. Hefti F, Melamed E, Wurtman RJ (1980) Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 195: 123-137
8. Heikkila RE, Cabbat FS, Manzino L, Duvoisin RC (1981) Potentiation by deprenyl of 1-dopa induced circling in nigral-lesioned rats. Pharmacol Biochem Behav 15: 75-79
9. Heinonen EH, Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand 84 [Suppl] 136: 44-59
10. Hudson JL, van Horne CG, Strömberg Y, Brock S, Clyton J, Masserano J, Hofferm BJ, Gerhardt GA (1993) Correlation of apomorphine-and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626: 167-174
11. Knoll J (1978) The possible mechanism of action of (-)deprenyl in Parkinson's disease. J Neural Transm 43: 177-198
12. König JFR, Klippel RA (1963) The rat brain: a stereotaxic atlas of the forebrain and lower parts of the brain stem. Williams & Wilkins, Baltimore
13. Lange KW, Riederer P, Youdim MBH (1994) Biochemical actions of 1-deprenyl. Clin Pharmacol Ther 56: 734-741
14. Marsden CD (1990) Parkinson's disease. Lancet i: 948-952
15. Pérez V, Marco JL, Fernández-Alvarez E, Unzeta M (1999a) Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br J Pharmacol 127: 869-876
16. Pérez V, Marco JL, Fernández-Alvarez E, Unzeta M (1999b) Involvement of Ca2+ in dopamine release in striatal slices by PF9601N and 1-deprenyl. Neurobiology (in press)
17. Pycock CJ (1980) Turning behaviour in animals. Neuroscience 8: 461-514
18. Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542-544
19. Schwarting RKW, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50: 275-331
20. Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand 367: 69-93
21. Watchel SR, Abercrombie DE (1994) L-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63: 108-117